BioXcel receives positive FDA preliminary comments ahead of pre-sNDA meeting

BioXcel Therapeutics, Inc.

Positive preliminary FDA meeting comments received August 14, 2025.
Pre-sNDA meeting scheduled for August 20, 2025 to align on sNDA submission format and content.
Company evaluating feedback and plans to provide update next week.

item 8.01

BioXcel Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-079042

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.